DHT and Hair Loss in Men Over 40: What's Actually Happening

Key Takeaways

• DHT (dihydrotestosterone) forms when the enzyme 5-alpha reductase converts testosterone; it binds to androgen receptors in scalp follicles 3 to 5 times more potently than testosterone itself
• Around 50% of men develop visible androgenetic alopecia (AGA) by age 50
• DHT levels stay more stable than testosterone as men age past 40, worsening the DHT-to-testosterone ratio
• Finasteride reduces scalp DHT by approximately 70%; dutasteride reduces it by approximately 90%
• Both drugs require continuous use; stopping reverses the benefit within 12 months
• Natural approaches (saw palmetto, pumpkin seed oil) have some evidence but are far less effective than prescription treatment
• Hair follicles permanently atrophy at advanced stages; early intervention produces far better outcomes

Around 50% of men develop visible hair loss by age 50. Dihydrotestosterone (DHT) drives this in the vast majority of cases, not testosterone itself. A natural experiment confirmed the causal role: men with a rare genetic 5-alpha reductase deficiency produce minimal DHT and do not develop male pattern baldness, regardless of testosterone levels. Understanding this mechanism tells you which treatments actually work, which ones are marketing noise, and what you risk if you block DHT.

What DHT Is and How It Destroys Hair Follicles

DHT forms when the enzyme 5-alpha reductase (5AR) converts testosterone into dihydrotestosterone. DHT binds to androgen receptors 3 to 5 times more potently than testosterone, making it the most active androgen in several tissues, including scalp hair follicles.

Inside a hair follicle, androgen receptors sit in the dermal papilla cells that control the hair growth cycle. When DHT binds these receptors, it triggers a miniaturization process: the follicle shrinks with each successive hair cycle, producing progressively thinner and shorter hairs until it stops producing hair entirely. Clinicians call this androgenetic alopecia (AGA), the technical term for male pattern baldness.

Two isoforms of 5-alpha reductase matter here. Type 2 dominates in scalp follicles and the prostate. Type 1 is more active in skin and liver. Most approved hair loss drugs target one or both enzymes.

The Hamilton-Norwood scale classifies AGA from Stage I (minimal recession at the temples) to Stage VII (a narrow horseshoe fringe remaining). By Stage VI or VII, follicles have permanently atrophied and no drug reverses the loss.

Why Hair Loss Accelerates After 40

Testosterone falls roughly 1 to 2% per year from the mid-30s onward. DHT falls more slowly, because 5-alpha reductase activity increases with age. The result is a worsening DHT-to-testosterone ratio: men over 40 often carry higher DHT relative to total testosterone than they did at 25.

Two additional factors compound this. First, androgen receptor sensitivity in scalp follicles can increase with age. Follicles that resisted DHT in a man's 30s can become susceptible as receptor expression shifts. Second, the anagen (active growth) phase of the hair cycle shortens with age, giving follicles less recovery time between DHT exposures.

Body fat also plays a role. Visceral fat stores aromatase, which converts testosterone to estrogen, and also increases local 5-alpha reductase activity. Men with excess midsection fat tend to show both elevated estrogen and elevated DHT, a hormonal pattern that accelerates AGA regardless of total testosterone.

A 2019 analysis published in the Journal of the American Academy of Dermatology confirmed that each decade of age is an independent predictor of AGA severity, separate from genetic factors.

The Genetic Factor: Why Some Men Lose Hair Earlier

Androgenetic alopecia requires two things: DHT, and scalp follicles that are sensitive to it. The sensitivity is almost entirely genetic.

The primary gene is the androgen receptor (AR) gene, located on the X chromosome. Sons inherit their X chromosome from their mother, which is why the "check your maternal grandfather" heuristic has some basis. The actual inheritance is polygenic: hundreds of genetic loci contribute, not one gene in isolation.

A 2017 genome-wide association study published in Nature Communications identified more than 200 genetic loci associated with AGA. Men who inherit higher AR expression or more sensitive AR variants experience follicle miniaturization at lower DHT concentrations. This explains why some men with high testosterone and high DHT retain full hair into their 70s, while others start thinning in their 20s with average hormone levels.

Genetic testing (HairDX and similar services) can identify which variants you carry. The test identifies relative risk but cannot predict timing or severity. A positive result changes nothing about available treatment options: the drugs are the same regardless of your genotype. Genetic testing is more useful for confirming a diagnosis than for guiding treatment.

Proven Medical Treatments

Two treatment classes have Level 1 evidence for DHT-driven hair loss.

5-Alpha Reductase Inhibitors

Finasteride (1 mg/day) inhibits type 2 5-alpha reductase, reducing scalp DHT by approximately 70%. A 2-year pivotal study published in the New England Journal of Medicine (Kaufman et al., 1998, n=1,553 men) found that 83% of men on finasteride stopped losing hair and 66% showed measurable regrowth, compared to continued loss in 72% of placebo recipients.

Dutasteride (0.5 mg/day) inhibits both type 1 and type 2 5-alpha reductase, reducing total DHT by approximately 90%. A 2020 meta-analysis in the Journal of the American Academy of Dermatology concluded dutasteride produces superior hair density scores compared to finasteride, with a modestly higher risk of sexual side effects.

Both drugs require 6 to 12 months before results appear, require continuous use, and reverse within 12 months of stopping. Neither cures AGA. They suppress the process while you take them.

Minoxidil

Minoxidil (Rogaine) does not block DHT. It extends the anagen phase and increases blood flow to follicles. It works as an adjunct to a 5AR inhibitor, not as a standalone treatment for DHT-driven loss. Oral minoxidil (2.5 to 5 mg/day) shows stronger efficacy than topical minoxidil in recent head-to-head trials.

Natural DHT Blockers: What the Research Shows

Several compounds inhibit 5-alpha reductase with weaker but real effects.

Saw palmetto (Serenoa repens, 320 mg/day) A 2012 randomized trial in the Journal of Alternative and Complementary Medicine compared saw palmetto to finasteride over 24 weeks. Finasteride outperformed by a wide margin: 66% of finasteride users showed improvement versus 38% on saw palmetto. Saw palmetto is substantially less potent but carries a lower side-effect burden. Men who refuse prescription drugs sometimes use it as a harm-reduction measure rather than a comparable alternative.

Pumpkin seed oil (400 mg/day) A 2014 randomized, double-blind trial published in Evidence-Based Complementary and Alternative Medicine found pumpkin seed oil produced a 40% increase in hair count versus placebo over 24 weeks. The sample was small (76 men), but results reached statistical significance. The mechanism is partial 5AR inhibition via beta-sitosterol and related phytosterols.

Zinc Zinc inhibits 5-alpha reductase in laboratory studies and acts as a cofactor for 5AR enzymes. Deficiency correlates with increased DHT production. Correcting a genuine zinc deficiency may reduce 5AR activity. Supplementing above adequacy has no additional benefit for DHT. For context on zinc's broader effects on testosterone, see the zinc and testosterone guide for men over 40.

Natural options work as adjuncts, not replacements for medical treatment.

The Real Tradeoffs of Blocking DHT

DHT is not just a hair-loss driver. It plays functional roles across several systems, and blocking it carries tradeoffs worth understanding before starting treatment.

Sexual function and libido. DHT is more potent than testosterone at androgen receptors in penile tissue and influences libido. Finasteride clinical trials report sexual side effects (reduced libido, erectile dysfunction, ejaculatory changes) in 3 to 5% of men. A subset, called "post-finasteride syndrome" in the literature, report persistent sexual or mood effects after stopping the drug. This remains contested in terms of prevalence and mechanism, but it is documented. Men considering finasteride should discuss this risk with their prescribing physician.

Muscle maintenance. DHT contributes to satellite cell activation and muscle protein synthesis, though its role is secondary to testosterone. Men with declining testosterone who add a 5AR inhibitor reduce both DHT and one component of anabolic signaling. This effect is modest in clinical practice, but men already working to maintain muscle mass over 40 should factor it in. The free testosterone calculator can help identify whether your androgen levels are already below optimal ranges.

Prostate health. This tradeoff works in your favor. 5-alpha reductase inhibitors are prescribed for benign prostatic hyperplasia (BPH) precisely because they shrink the prostate by reducing DHT. Long-term use is associated with reduced risk of prostate cancer requiring intervention. For men over 40 monitoring prostate health, this is a genuine benefit, not a cost.

Neurosteroids and mood. 5-alpha reductase produces neurosteroids in brain tissue that modulate GABA receptors and influence mood and anxiety. Dutasteride crosses the blood-brain barrier more readily than finasteride and may carry a higher risk of mood-related side effects. Men with a history of anxiety or depression should discuss this mechanism with their doctor before starting either drug.

When to Act and What to Expect

Hair follicles recover only if treated before permanent atrophy sets in. Stage I through IV on the Hamilton-Norwood scale represents the intervention window: follicles are still alive, still producing some hair, and still capable of recovery with treatment. At Stage VI or VII, DHT has completed its work. No drug reverses that.

Waiting is not a neutral choice. Each hair growth cycle under DHT exposure causes more miniaturization. Men who notice thinning at the crown or a receding hairline at the temples are often in the treatable window. Delaying treatment by two or three years means two or three years of progressive, largely preventable loss.

A dermatologist or trichologist can assess your specific pattern, confirm the diagnosis as AGA versus other causes, and recommend appropriate treatment. Other causes of hair loss include telogen effluvium (diffuse shedding from physiological stress), thyroid dysfunction, iron deficiency, and alopecia areata, all of which require different approaches.

Blood work worth reviewing before starting treatment: total and free testosterone, DHT (where your lab offers it), thyroid-stimulating hormone (TSH), ferritin, and a complete blood count. This rules out reversible hormonal causes. Men with low total testosterone should address that first, since some low-T treatments also affect DHT. See testosterone levels by age for reference ranges.

Men interested in naturally supporting their androgen profile while managing DHT can read the free testosterone optimization guide for protocols that don't depend on pharmaceuticals.

FAQ

What is DHT and what does it do?

DHT (dihydrotestosterone) is an androgen hormone formed when 5-alpha reductase converts testosterone. It binds to androgen receptors 3 to 5 times more potently than testosterone. In scalp follicles, DHT triggers miniaturization: the follicle shrinks over successive hair cycles, producing thinner hairs until production stops entirely.

Does high testosterone cause hair loss?

High testosterone does not cause hair loss directly. DHT, derived from testosterone via 5-alpha reductase, triggers follicle miniaturization in genetically susceptible men. A man with high testosterone but low 5AR activity or low androgen receptor sensitivity in scalp follicles can have elevated T and full hair. The issue is DHT production and follicle sensitivity, not testosterone level.

Can you stop DHT-related hair loss?

Yes, with consistent medical treatment. Finasteride halts progression in 83% of men; dutasteride achieves even higher rates. Both require continuous use. Stopping reverses the benefit within 12 months. The earlier treatment starts relative to follicle atrophy, the better the outcome.

Will blocking DHT affect testosterone?

5-alpha reductase inhibitors reduce DHT but typically raise total testosterone, because blocking the conversion pathway reduces DHT clearance from the testosterone pool. Total testosterone often rises 15 to 20% on finasteride. Free testosterone may also increase modestly. These changes do not offset the sexual and mood side effects that some men experience.

How do I know if my hair loss is DHT-related?

Pattern is the key indicator. DHT-driven loss follows the Hamilton-Norwood progression: temporal recession and crown thinning that gradually merge. Diffuse thinning across the entire scalp (not patterned) is more often telogen effluvium from stress, illness, thyroid dysfunction, or iron deficiency. A dermatologist can confirm the diagnosis and check for other contributing factors with blood work.

This article is for informational purposes only and does not constitute medical advice. Consult your doctor or a board-certified dermatologist before starting any treatment for hair loss, including prescription 5-alpha reductase inhibitors.